Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab and Cemiplimab as Total Neoadjuvant Therapy (TNT) For Melanoma
NCT07527325Phase 2Not yet recruiting
- Sponsor
- University of California, Irvine
- Start
- Dec 2026
- Primary completion
- Feb 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of fianlimab in melanoma, sponsored by University of California, Irvine. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
fianlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07527325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07527325.